ADCs | Therapeutic Targets | Precision Oncology 📸1: Global ADC Sales by Target, 2023 📸2: 16 ADCs currently approved for market use by the US FDA

Capacity Expansion | EUCEPs | Regulatory Approvals Clopidogrel Bisulphate production capacity was increased from 180 MTPA to 240 MTPA at Unit-5 EDQM granted CEP for Mesalazine & Quetiapine Fumarate Regulatory approval for Ibuprofen from China’s CDE, NMPA Ref: IOL Chemicals

CDMOs & CMOs | Strategic Response | Integrated Manufacturing 📸1: At Laurus Labs, we continue to scale our CDMO operations to meet growing demand, with targeted investments in infrastructure, innovation & partnerships 📸2: Strengthening collaborations with CMOs to augment

Dengue Vaccine | Phase III | Make in India 🇮🇳 📸1: DengiAll has completed Phase I/ll studies with more than 94% of participants showing robust and balanced immune response (Ref: Panacea Biotec) 📸2: India's first Phase 3 trial hits 50% enrolment mark, early data shows no safety

Caplyta (Lumateperone) ➡️CNS Pharmacology➡️ Chemistry & Intermediates 📸1: CAPLYTA, a remarkable medicine with balanced Pharmacology that delivers robust efficacy, combined with a favorable tolerability profile for neuropsychiatric disorders. First & only USFDA-approved

Paclitaxel | Settlement of Disputes | Panacea/Apotex 📸1: Intimation of Settlement of Disputes with Apotex Inc., Canada 📸2: Pursuant to this settlement, PBPL shall receive a net amount of US$ 2.0 million from Apotex in the manner as aforesaid, which will enhance profitability

Animal Health | Companion Animal | Pet Health Our pipeline is becoming more diversified with new projects in Companion Animals being added to enrich our product portfolio. Additionally, our strong portfolio of Business Development projects maturing in 2024, combined with our

Pharma Intermediates | APIs | Supply Chain Shift European market-share has decreased & dependency increased Regulatory Starting Materials (RSM) - RSMs are first chemical substances compliant with GMP mainly imported from cost competitive regions (China & India) to Europe GMP

Pentavalent Vaccine | UNICEF/GAVI | Child Immunization The pentavalent global market estimated to reach ~ 318.4 million doses in 2023 1. LMICs represent the largest share of this volume, with 175.6 million doses (55% of volume) 2. UMICs with 74.2 million doses, (23%), 3. LICs

Pharma Intermediates | R&D | Chemistry Synthesis With the objective of early identification & attaining early development, we constantly seek to introduce new product verticals and develop our R&D capabilities to distinguish ourselves from our competitors particularly with a

R&D Spend | CDMO Employment | ANDAs & DMFs In Sept 2024, Laurus Labs inaugurated a cutting-edge R&D facility at IKP Knowledge Park, Telangana. This 200,000 square-foot centre, established with an initial investment of INR 250 crore, is designed to bolster our CDMO business and

Pharma APIs | Capacity Enhancement | Regulatory Expansion FY25 was marked by strategic consolidation & investments focused on capacity enhancement, improved utilization, cost control & regulatory expansion. Our strong backward integration model continues to drive cost control,

Pharma APIs | Complex Intermediates | Therapy Segment 📸1: Oncology was the largest therapy segment in terms of APl products. Global rise in cases of cancer, combined with federal aims at curbing the disease are bound to boost growth of this segment. Oncology drugs are also

Animal Health | Companion Animal | APIs & FDF Sequent 1.0 - Building blocks for growth (2010-2019) Sequent 2.0 - Sharpening focus (2020-2025) Sequent 3.0 - Creating a unique, differentiated global animal health player (2025 onwards) Ref: Sequent Scientific 2025

CDMOs | APIs & FDF | Integrated Manufacturing Laurus Labs Offerings – Therapeutic Class Cardiovascular | Anti-Diabetic | Anti-Asthma Gastrointestinal | Oncology | Ophthalmic products Animal Health | ARVs | Hepatitis C

Product Portfolio | Key Customers | Pediatric Vaccines Vaccines - Leading player in key pediatric vaccines Vaccines - Product Portfolio & Key Customers Ref: Panacea Biotec

Prostate Cancer | Patient Progression | Darolutamide Darolutamide Phase 3 trials covering almost all prostate cancer stages Ref: Orion 2025

Ethanol Blending | Biofuels | E27 Fuel India plans E27 ethanol fuel blend as push for alternative fuels intensifies Ref: ET Auto July 2025

ADCs | Complex Manufacturing | Oncology Therapy To create a successful ADC, the developer needs to connect 3 complex components that carry distinct challenges 1. The mAb & its affinity to targeted antigens 2. The linker stability in circulation 3. The cytotoxic payload's

Darolutamide | Prostate Cancer | Added Indication Darolutamide receives EU approval in third indication for patients with advanced prostate cancer Ref: Orion 2025